Maslowski John Michael 4

Accession 0001628280-19-015076

CIK 0000357097other

Filed

Dec 12, 7:00 PM ET

Accepted

Dec 13, 4:12 PM ET

Size

23.9 KB

Accession

0001628280-19-015076

Form 4

Period: 2019-12-13

VP, Scientific Affairs

Transactions

Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−908→ 0 total
Exercise: $232.50Exp: 2021-01-14→ Common Stock (908 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,334→ 0 total
Exercise: $44.10Exp: 2024-05-13→ Common Stock (1,334 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,668→ 0 total
Exercise: $52.95Exp: 2025-01-20→ Common Stock (6,668 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−6,667→ 0 total
Exercise: $34.05Exp: 2026-03-01→ Common Stock (6,667 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−16,667→ 0 total
Exercise: $9.94Exp: 2026-12-16→ Common Stock (16,667 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−20,000→ 0 total
Exercise: $3.45Exp: 2028-01-25→ Common Stock (20,000 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,167→ 0 total
Exercise: $82.35Exp: 2023-07-19→ Common Stock (1,167 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−1,334→ 0 total
Exercise: $74.25Exp: 2024-01-17→ Common Stock (1,334 underlying)
Disposition to Issuer
Option to Purchase Common Stock
2019-12-13−100,000→ 0 total
Exercise: $1.78Exp: 2029-04-12→ Common Stock (100,000 underlying)
Disposition to Issuer
Common Stock
2019-12-13$3.00/sh−3,164$9,492→ 0 total

Footnotes (2)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
[F2]Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.

Documents

1 file

Fibrocell Science, Inc.

CIK 0000357097

Entity typeother